Histone deacetylase (HDAC) inhibitors induce differentiation and/or apoptosis in a variety of cell types by activating transcription of target genes. Activation of the death receptor (DR) pathway by tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) induces apoptosis preferentially in cancer cells. Here, we investigated the intracellular mechanisms by which HDAC inhibitors (suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide, MS-275 and trichostatin A) enhance the apoptosis-inducing potential of TRAIL in breast cancer cells in vitro. A synergism in apoptosis was observed in both TRAIL-sensitive and -resistant cells upon sequential treatments with HDAC inhibitors followed by TRAIL. HDAC inhibitors synergized with TRAIL by inducing DRs DR4/TRAIL-R1 and DR5/TRAIL-R2 through NFjB activation and some of the proapoptotic members of the Bcl-2 family, and engaging the mitochondrial pathway. The ability of HDAC inhibitors to sensitize TRAIL-resistant cells suggests that HDAC inhibitors may induce fundamental alterations in cell signaling pathways. Thus, the sequential treatments with HDAC inhibitors followed by TRAIL may be used as a new therapeutic approach for the treatment of human cancers.
Introduction
Histones are part of the core proteins of nucleosomes. The recruitment of histone acetyltransferase (HATs) and histone deacetylases (HDACs) is considered a key step in proliferation, differentiation and apoptosis (Kouzarides, 1999; Glass and Rosenfeld, 2000) . Altered HAT or HDAC activity is associated in the formation and development of certain human cancers by changing the expression pattern of various genes (Grignani et al., 1998; Lin et al., 1998) . Hyperacetylation of the Nterminal tails of histones H3 and H4 correlates with gene activation, whereas deacetylation mediates transcriptional repression (Strahl and Allis, 2000) . Treatment of malignant cells with HDAC inhibitors regulates only a small number (1-2%) of genes, as examined by DNA microarray studies (Van Lint et al., 1996) . HDAC1 interacts directly with other transcription repressors, including all three of the pocket proteins, Rb, p107 and p130 and YY1. HDAC1 is believed to achieve transcription repression by locally deacetylating histones, leading to a compact nucleosomal structure that prevents transcription factors from accessing DNA to promote transcription. Inhibition of HDAC activity results in the activation of p21 promoter activity (a cyclin-dependent kinase inhibitor), independent of p53 activity. Furthermore, HDAC1 knockout mice were embryonic lethal, possibly due to a proliferative defect upon unrestricted expressions of the cell cycle inhibitors p21 and p27 (Lagger et al., 2002) . Recent studies have shown that inhibition of HDAC activity induces apoptosis in various types of cancer (Bernhard et al., 1999 (Bernhard et al., , 2001 Burgess et al., 2001; .
HDACs play important roles in modulating chromatin structure. The HDACs can be divided into three classes (Gray and Ekstrom, 2001) . Class I contains HDAC 1, 2, 3, and 8, which have a single deacetylase domain at the N-termini and diversified C-terminal regions. Class II includes HDAC 4, 5, 6, 7, 9 , and 10 with a deacetylase domain at a more C-terminal position. In addition, HDAC 6 contains a second Nterminal deacetylase domain, which can function independently of its C-terminal counterpart. Recently, mammalian homologs of the yeast Sir2 protein have been identified, forming a third class of deacetylases. All of these HDACs apparently exist in the cell as subunits of multiprotein complexes. Class II HDACs have been shown to translocate from the cytoplasm to the nucleus in response to external stimuli, whereas class I HDACs are constitutively nuclear and play important roles in dynamic gene regulation (McKinsey et al., 2000) . Recently, a number of HDAC inhibitors have been identified that induce cultured tumor cells to undergo growth arrest, differentiation, and/or apoptosis (Newmark et al., 1994; Yoshida, 1994; Kwon et al., 1998; Nakajima et al., 1998) . These agents also inhibit the growth of cancer cells in animal models (Cohen et al., 1999; Glick et al., 1999; Kim et al., 1999; Saito et al., 1999; Butler et al., 2000) . Therefore, HDAC inhibitors are considered as candidate drugs in cancer therapy (Kramer et al., 2001; Marks et al., 2001) .
TNF-related-apoptosis-inducing-ligand (TRAIL)/ Apo2 ligand (Apo-2L) selectively induces apoptosis in tumor cells, both in culture and in vivo, while sparing most normal cells (Pan et al., 1997b; Sheridan et al., 1997; Singh et al., 2003) . TRAIL induces apoptosis by binding to death-domain containing receptor TRAIL-R1 (death receptor (DR)4/Apo-2A) (Pan et al., 1997b) and TRAIL-R2 (DR5/TRICK/Killer) (Pan et al., 1997b; Sheridan et al., 1997; Walczak et al., 1997) . TRAIL can also bind to two decoy receptors (DcR), TRAIL-R3 (TRID/DcR1/LIT) (Degli-Esposti et al., 1997b; Pan et al., 1997a; Sheridan et al., 1997) and TRAIL-R4 (TRUNDD/DcR2) (Degli-Esposti et al., 1997a; Marsters et al., 1997) , with DcR1 lacking a death domain and DcR2 having a nonfunctional death domain. These DcRs do not transduce apoptotic signals, and are believed to compete with the DRs for ligand binding and thereby inhibit ligand-induced apoptosis in normal cells. The effectiveness of TRAIL can be increased by providing sufficient amounts of receptors on the surface of the tumor cells. Although TRAIL is capable of inducing apoptosis in tumor cells of diverse origin (Chen et al., 2001; Srivastava, 2001; Kandasamy and Srivastava, 2002) , we and others have recently shown that the majority of breast cancer cell lines are resistant to TRAIL (Keane et al., 1999; Singh et al., 2003) , suggesting that TRAIL alone cannot be used for breast cancer therapy. Therefore, understanding the molecular mechanisms of TRAIL resistance and ways to sensitize these resistant cells to undergo apoptosis will be a major advantage for cancer therapy.
The objectives of this study were to investigate the intracellular mechanisms by which HDAC inhibitors (MS-275, m-carboxycinnamic acid bis-hydroxamide (CBHA), suberoylanilide hydroxamic acid (SAHA), and trichostatin A (TSA)) enhance the apoptosis-inducing potential of TRAIL, and sensitize TRAIL-resistant cells in vitro. Here, we demonstrate that the sequential treatments of cells with HDAC inhibitors followed by TRAIL are more effective in inducing apoptosis than the concurrent treatments or single agent alone. The combinations of HDAC inhibitors and TRAIL result in a synergistic induction of apoptosis both in TRAILsensitive and -resistant cells due to upregulation of DR4 and/or DR5, activations of caspase-3, -9, and -8, inductions of proapoptotic members of Bcl-2 family, and inhibition of Bcl-2 and/or Bcl-X L . Thus, sequential treatments of cancer cells with HDAC inhibitors followed by TRAIL can be used to kill both TRAILsensitive and -resistant breast cancer cells.
Results

Effects of HDAC inhibitors and TRAIL on apoptosis
We have recently shown that several breast cancer cell lines are resistant to TRAIL (Singh et al., 2003) . We therefore sought to examine whether HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in TRAIL-sensitive MDA-MB-231 cells, and sensitize  TRAIL-resistant MDA-MB-468 cells. HDAC inhibitors  (MS-275 , CBHA, SAHA, and TSA) induced apoptosis in both MDA-MB-231 and MDA-MB-468 cell lines (Figure 1 ). TRAIL induced apoptosis in MDA-MB-231 cells, but not in MDA-MB-468 cells. The sequential treatment of MDA-MB-231 cells with HDAC inhibitors followed by TRAIL induced apoptosis in a synergistic manner. Pretreatment of TRAIL-resistant MDA-MB-468 cells with HDAC inhibitors followed by TRAIL resulted in sensitization of these cells to apoptosis. Interestingly, sequential treatments of cancer cells with HDAC inhibitors followed by TRAIL were more effective in inducing apoptosis than the concurrent treatments or single agent alone (data not shown). By comparison, HDAC inhibitors and TRAIL, alone and together, had no significant effect on apoptosis of normal human mammary epithelial cells (HMECs). These data suggest that HDAC inhibitors can enhance the apoptosis-inducing potential of TRAIL in TRAILsensitive cells, and sensitize TRAIL-resistant cells without affecting normal HMECs.
To further define the interactions of TRAIL with SAHA on apoptosis, we performed isobolographic analyses where we determined the interactive effects of different TRAIL concentrations on the ED50 of SAHA in inducing apoptosis. Isobolographic analysis provides a mathematical basis for assessing whether biological responses induced by mixtures of agents are greater, equal or smaller than would have been expected on the basis of the individual activities of the component agents and the concept of dose additivity (Gessner, 1995) . Figure 1d shows that plotting the TRAIL concentration versus the ED50 for SAHA (cotreatment) yields an almost linear relationship, that is, a function of simple additivity. All data points and the corresponding 95% confidence intervals overlap with the function obtained by linear regression. This linear relationship indicates that TRAIL and SAHA exert only an additivity effect on inhibiting cell viability. In contrast, the isobolographic analysis shows a hyperbolic curve when cells were pretreated with SAHA, followed by TRAIL (Figure 1e ). All data points fall below the line of simple additivity and the corresponding 95% confidence intervals. The closer location of empirically observed data points in vicinity to the origin of the graph clearly demonstrates a synergistic interaction of these two cell death stimuli. Thus, synergism appears to fully depend on the sequential treatment of cells with SAHA followed by TRAIL.
Regulation of DRs by HDAC inhibitors
TRAIL induces apoptosis by binding to DRs and activation of the caspase cascade (Ashkenazi and Dixit, 1999; Srivastava, 2000; Suliman et al., 2001) . We have recently shown that DRs DR4 and/or DR5 can be upregulated with chemotherapeutic drugs and irradiation (Singh et al., 2003; Shankar and Srivastava, 2004; Shankar et al., 2004a, b) , and thus enhance the effectiveness of TRAIL. Since HDAC inhibitors synergize with TRAIL in inducing apoptosis, we sought to examine whether this interaction is due to upregulation of DR4 and/or DR5. We, therefore, examined the expressions of DRs by HDAC inhibitors using RNase Protection Assay (RPA) (hAPO-3D probe set, caspase-8, DR5, DR4, L32, and GAPDH, PharMingen). HDAC inhibitors MS-275, SAHA, and TSA induced expressions of caspase-8, DR5, and DR4 in MDA-MB-231 cells in a time-dependent manner (Figure 2a) . Similarly, HDAC inhibitors induced expressions of caspase-8, DR4, and DR5 in MDA-MB-468 cells (Figure 2b-d) .
We next confirmed the inductions of HDAC inhibitor-induced DRs by ELISA. Breast cancer MCF-7, MDA-MB-231, and MDA-MB-468 cells were treated with MS-275, SAHA, and TSA for 24 or 48 h to measure the expressions of DR4 and DR5. These HDAC inhibitors significantly induced DR4 and DR5 in MCF-7, MDA-MB-231, and MDA-MB-468 cells (data not shown). Since DRs have to translocate to the cell surface after their synthesis, we confirmed the expressions of DR4 and DR5 receptors on the cell surface by flow-cytometric analysis using monoclonal antibodies. MDA-MB-231 cells were treated with MS-275, CBHA, SAHA, and TSA for 24 h, and the expressions of DR4 and DR5 receptors on the cell surface were measured (Figure 2e and f) . The expressions of DR4 and DR5 on the cell surface were significantly higher in cells treated with HDAC inhibitors than untreated control. We next examined the expression of DcRs DcR1 and DcR2 in MDA-MB-231 and MDA-MB-468 cells treated with HDAC inhibitors (data not shown). MS-275, CBHA, SAHA, and TSA (1 mM), CBHA (1 mM), SAHA (1 mM), and TSA (100 nM) for 24 h. Expressions of DR4 and DR5 were measured by flow-cytometric analysis had no effect on the expression of DcRs. These data confirmed the above findings that HDAC inhibitors induced the expressions of DR4 and DR5 at the mRNA and protein levels (total and cell surface). The induction of DRs by these drugs appears to be independent of p53 status as p53 wild-type (MCF-7) and p53 mutant (MDA-MB-231 and MDA-MB-468) cell lines were similarly sensitized to TRAIL by HDAC inhibitors.
Regulation of Bcl-2 family members by HDAC inhibitors
Bcl-2 family members have been found to regulate apoptosis induced by stress stimuli primarily at the level of mitochondria (Green and Reed, 1998; Gross et al., 1999a; Srivastava et al., 1999b; Korsmeyer et al., 2000) . We, therefore, examined the effects of HDAC inhibitors on the expressions of Bcl-2 family members by RPA (hAPO-2C multiprobe set, PharMingen) ( Figure 3 ). MS-275, CBHA, SAHA, and TSA significantly induced Bad, Bik, Bak, and Bax expressions in TRAIL-sensitive MDA-MB-231 cells ( Figure 3a ). These drugs also significantly induced Bcl-X, which was later confirmed to be Bcl-Xs by Western blot analysis (data not shown).
Similarly, MS-275, CBHA, SAHA, and TSA increased the ratios of Bad/Bcl-X and Bak/Bcl-X in MDA-MB-468 cells (Figure 3b and c).
We next confirmed the expressions of Bcl-2 family members by Western blot analysis in MDA-MB-231 and MDA-MB-468 cell lines (Figure 3d-g ). HDAC inhibitors induced expressions of proapoptotic proteins Bak, Bad, Bax, Bcl-X S , PUMA, Noxa, and Bim, and inhibited expressions of antiapoptotic proteins Bcl-2 and Bcl-X L in both the cell lines. These data suggest that proapoptotic proteins may play a role, at least in part, in the synergistic interactions among HDAC inhibitors and TRAIL.
Regulation of mitochondrial functions by Bcl-2 and Bcl-X L
We and others have shown that Bcl-2 and Bcl-X L block drug-induced mitochondrial membrane potential (MMP) and apoptosis by acting at the level of outer mitochondrial membrane (Reed et al., 1996; Srivastava et al., 1999b; Thomas et al., 2000) . In order to assess the involvement of mitochondrial pathway on the synergistic interaction of HDAC inhibitors and TRAIL on apoptosis, we used TRAIL-sensitive MDA-MB-231 and TRAIL-resistant MDA-MB-468 cells overexpressing Bcl-2, Dloop Bcl-2, Bcl-X L , and Dloop Bcl-X L (Srivastava et al., 1999c; Singh et al., 2003) . We used Dloop Bcl-2 (D32-80 aa) and Bcl-X L (D26-83 aa) because all the functional phosphorylation sites are located within the loop regions of these proteins (Srivastava et al., 1999a) . MS-275, SAHA, and CBHA induced apoptosis in both the cell lines ( Overexpression of Bcl-2, Dloop Bcl-2, Bcl-X L , or Dloop Bcl-X L also inhibited apoptosis in both cell lines when pretreated with HDAC inhibitors, followed by treatment with TRAIL. These data suggest that the mitochondrial pathway plays a major role in apoptosis induced by the synergistic interactions of HDAC inhibitors and TRAIL, because Bcl-2 and Bcl-X L proteins mainly exert their biological activity by anchoring on the outer mitochondrial membrane.
HDAC inhibitors augment TRAIL-induced apoptosis through caspase activation
The apoptotic death of cells requires proteolytic activation of caspases which are synthesized as latent proenzymes (Nicholson et al., 1995; Salvesen, 1999) . Once activated, caspases cleave a wide range of molecules (e.g. poly(ADP-ribose) polymerase (PARP)) that eventually result in the dismantlement of cells (Kaufmann et al., 1993; Singh et al., 2003) . Active caspases can be specifically inhibited by inhibitors of apoptosis (IAP). IAP antagonists (Smac/DIABLO, Omi/HtrA2, and GSPT1/eRF3) compete with caspases for IAP-binding and consequently relieve caspases and promote cell death. Since HDAC inhibitors augment TRAIL-induced apoptosis, we sought to examine the mechanisms of this interaction by measuring the expressions of IAPs (XIAP, survivin, cIAP1, and cIAP2) and activation of caspase-9 and -3 by their cleavage. MDA-MB-231 and MDA-MB-468 cells were treated with MS-275 and TSA for 24 and 48 h, and the expressions of IAPs were measured by the Western blot analysis. MS-275 and TSA inhibited expressions of XIAP and cIAP2, and cleaved cIAP1 (Figure 5a and b). These HDAC inhibitors had no effect on survivin expression.
We next examined the cleavage of caspase-3, -9, and PARP by Western blot analysis (Figure 5c and d) . MDA-MB-231 and MDA-MB-468 cells were treated with MS-275, CBHA, SAHA, and TSA for 24 h, followed by treatments with TRAIL for another 24 h, and cleavage of caspase-3, -9, and PARP was measured. Treatment of cells with the HDAC inhibitors resulted in a slight cleavage of caspase-3, -9, or PARP (Figure 5c and d). Furthermore, the combinations of HDAC inhibitors and TRAIL enhanced the cleavage of caspase-3, -9, and PARP in both the cell lines.
To identify whether the augmentation of TRAILinduced apoptosis by HDAC inhibitors was mediated through caspase activation, cells were incubated with HDAC inhibitors, TRAIL, or their combinations in the presence or absence of a pan caspase inhibitor (z-ValAla-Asp-fluoromethylketone (z-VAD-fmk)) or a caspase-8 inhibitor (z-IETD) (Figure 5e ). The inhibition of caspase activity by z-VAD-fmk significantly blocked apoptosis induced by HDAC inhibitor alone, TRAIL alone, and the combinations of HDAC inhibitor and TRAIL. By comparison, z-IETD inhibited the effect of TRAIL alone, and the interactive effects of HDAC inhibitors and TRAIL on apoptosis. The z-IETD had no effect on apoptosis induced by HDAC inhibitors. These data suggest that caspase(s) activation plays a significant role in the synergistic interactions among HDAC inhibitors and TRAIL, and the caspase-8 is essential for the synergistic interactions. In order to assess the involvement of cell extrinsic (DR) pathway in the synergistic interactions between HDAC inhibitors and TRAIL, we used the dominant-negative FADD (DN-FADD). FADD is essential for recruitment of procaspase-8 to the active TRAIL-DISC (Suliman et al., 2001) . HDAC inhibitors induced apoptosis in MDA-MB-231 cells (Figure 5f ). All the HDAC inhibitors enhanced the apoptosisinducing potential of TRAIL. DN-FADD had no effect on HDAC inhibitor-induced apoptosis, but inhibited apoptosis induced by TRAIL alone or HDAC inhibitor plus TRAIL. These data suggest that the cell-extrinsic pathway is required for the synergistic interactions among HDAC inhibitors and TRAIL.
Since HDAC inhibitors induced cleavage of cIAP1, we sought to examine whether the cleavage was due to activation of caspase(s). Breast cancer cells were pretreated with z-VAD-fmk, followed by treatment with or without MS-275 or TSA (Figure 5g ). Treatment of MDA-MB-231 and MDA-MB-468 cells with MS-275 or TSA resulted in the cleavage of cIAP1. While ineffective alone, z-VAD-fmk inhibited MS-275 or TSA induced cleavage of cIAP1. These data suggest that cIAP1 contains a caspase cleavage site. Recent studies have shown the involvement of NFkB in the regulation of apoptosis Sovak et al., 1997; Cogswell et al., 2000; Franco et al., 2001; Chen et al., 2003) . In breast cancer cells, NFkB is constitutively active , and therefore may change the apoptotic response of HDAC inhibitors. In order to determine whether NFkB plays a role in HDAC inhibitor-induced apoptosis, we first examined the activation of NFkB in MDA-MB-231 cells ( Figure 6 ). MDA-MB-231 cells were treated with MS-275 for various times, and translocation of NFkB to the nucleus was examined by electrophoretic mobility shift assay (EMSA). The NFkB-binding activity was increased in a time-dependent manner in MDA-MB-231 cells after treatment with HDAC inhibitors, reaching a maximum at 2 h ( Figure 6a ). To further identify which NFkB subunits contribute to DNA-binding activity, we performed supershift assay with specific antibodies against different subunits of NFkB, that is, p50, RelA (p65), and c-Rel (Figure 6b) . Treatment of cells with MS-275 enhanced the NFkB-DNA-binding activity in MDA-MB-231 cells. Antibodies specific for the p50 and p65 subunits of NFkB caused significant supershift, whereas anti-c-Rel antibody has no effect. We next examined the DNA-binding activities of various subunits of NFkB in MDA-MB-231 cells treated with TSA (Figure 6c) . TSA enhanced the NFkB-DNA-binding activity in MDA-MB-231 cells. Incubation of nuclear extracts with an unlabelled consensus NFkB oligonucleotide completely abolished DNA binding, suggesting the specificity of NFkB bands. Antibodies specific for p50 and p65 subunits of NFkB caused significant supershifts. By comparison, no supershifted bands were observed with anti-c-Rel, anti-RelB, and anti-p52 antibodies, probably because of the nature of antibodies or absence of these subunits of NFkB in the nucleus.
We next examined the transcriptional activation of NFkB by luciferase reporter assay. MDA-MB-231 cells were transiently transfected with kB-luciferase reporter plasmids and the NFkB transactivity was measured (Figure 6d ). The data showed that NFkB transactivation was significantly induced by HDAC inhibitors in MDA-MB-231 cells, reaching a maximum level at 2 h.
The super-repressor mIkBa blocked the NFkB transactivity induced by HDAC inhibitors. Thus, these data suggest that HDAC inhibitors can induce NFkB-DNA binding and kB-dependent transcriptional activity in MDA-MB-231.
Since HDAC inhibitors induced expressions of DR4 and DR5, we sought to examine whether NFkB regulates the expressions of these DRs (Figure 6e) . Treatment of MDA-MB-231 cells with MS-275 resulted in the induction of DR4 and DR5. Inhibition of NFkB activation either by a mutant IkBa (super-repressor) or MG132 (a proteasome inhibitor) attenuated NFkB-induced DR4 and DR5 expressions. These data suggest that HDAC inhibitors regulate the expressions of DR4 and DR5.
We finally examined whether HDAC inhibitors regulate NFkB-dependent gene expression through regulation of NFkB subunits (Figure 6f ). MS-275 and TSA had no effect on the expression of p65, p50, and c-Rel in both MDA-MB-231 and MDA-MB-468 cells. These data suggest that HDAC inhibitors regulate gene expression without affecting the expression of NFkB subunits.
Discussion
Here we show that HDAC inhibitors (SAHA, MS-275, CBHA, and TSA) induce expressions of DRs (DR4 and/ or DR5), some of the proapoptotic members of Bcl-2 family (Bim, Noxa, PUMA, Bax, Bak, Bad, and Bik), and inhibit expressions of XIAP, Bcl-2, and Bcl-X L . Sequential treatments of cells with HDAC inhibitors followed by TRAIL cause a synergistic apoptotic response by engaging the mitochondrial (intrinsic) pathway. Similarly, chemotherapeutic drugs and irradiation upregulate DR4 and/or DR5 expression, thereby enhancing TRAIL-induced apoptosis in vivo Walczak et al., 1999; Chinnaiyan et al., 2000; Singh et al., 2003; Shankar et al., 2004a Shankar et al., , b, 2005 . Recently, the interactive effects of HDAC inhibitors and TRAIL on apoptosis have been demonstrated in other types of cancer (Hernandez et al., 2001; Zhang et al., 2003; Neuzil et al., 2004) . Thus, an increase in DR4 and DR5 levels by HDAC inhibitors is capable of enhancing apoptosis in response to added TRAIL in both TRAIL-sensitive and -resistant breast cancer cells. Since HDAC inhibitors enhance the (1 mM), CBHA (1 mM), SAHA (1 mM), or TSA (100 nM) for 24 h, followed by treatment with TRAIL (50 nM) for another 24 h. Western blot analysis was performed to measure the cleavage of caspase-3, -9, and PARP. Anti-actin antibody was used as a loading control. (e) MDA-MB-231 cells were pretreated with 50 mM z-VAD-fmk or z-IETD-fmk for 2 h, followed by treatment with MS-275 (1 mM), SAHA (1 mM), TSA (100 nM), or CBHA (1 mM), in the presence or absence of TRAIL (50 nM) for 48 h, and apoptosis was measured by annexin-V-FITC and PI staining. Data represent mean7s.d. *Significantly different from respective controls, Po0.05. (f) MDA-MB-231 cells were transiently transfected with either empty vectors or plasmids expressing DN-FADD. In addition, cells were cotransfected with control plasmids (pCMV-LacZ) encoding the b-galactosidase enzyme. After transfection, cells were treated with MS-275 (1 mM), SAHA (1 mM), TSA (100 nM), or CBHA (1 mM) in the presence or absence of TRAIL (50 nM) for 48 h, and apoptosis was measured by annexin-V-FITC and PI staining. Data represent mean7s.d. *Significantly different from respective controls, Po0.05. (g) Effects of a pan caspase inhibitor on HDAC inhibitor-induced cleavage of cIAP1. Breast cancer cells were pretreated with a pan caspase inhibitor (z-VAD-fmk; 10 mM) for 4 h, followed by treatment with or without MS-275 (1 mM) or TSA (100 nM) for 24 h. Western blot analysis was performed to measure the expression/cleavage of cIAP1. b-Actin was used as a loading control apoptosis-inducing potential of TRAIL in TRAILsensitive cells and sensitize TRAIL-resistant cells, the combination of HDAC inhibitor and TRAIL could be used as a viable option in cancer therapy. In contrast to cancer cells, HDAC inhibitors did not induce apoptosis in normal mammary epithelial cells probably because cancer cells are rapidly dividing where enhanced acetylation of histones will result in chromatin relaxation, thus specific gene transcription leading to apoptosis.
Our data indicate that sensitization of TRAILresistant breast cancer cells by HDAC inhibitors is independent of the p53 mutation state, suggesting the possibility that pathway(s) other than p53 may be involved in the upregulation of DR4 and/or DR5. We have demonstrated that cells harboring wild-type (MCF-7) and mutated (MDA-MB-231 and MDA-MB-468) p53 can be sensitized by chemotherapeutic drugs (Singh et al., 2003) , irradiation (Shankar and Srivastava, 2004; Shankar et al., 2004a) , and HDAC inhibitors (present study). Similarly, in other studies, DR5 is regulated by chemotherapeutic drugs independent of the p53 status, consistent with the suggestion that there are p53-independent pathways regulating DR expression (Keane et al., 1999; Nagane et al., 2000) . The effect of p53 on cell growth and apoptosis may be modulated through its deacetylation by a HDAC1-containing complex (Luo et al., 2000) . Therefore, modulating the transcriptional activity of p53 may be involved in the growth arrest and apoptosis induced by HDAC inhibitors. These data suggest that the combination treatment approach could target breast cancer cells harboring both wild-type and mutant p53. Regulation of DR expression may also depend on the type of insult, because the mode of actions of drugs used in previous studies are distinct (microtubule-and DNA-damaging drugs) , and thus the level of DR upregulation varied among them. It is possible that DNA lesions preferentially initiate downstream pathways that activate the transcription machinery for DR expression. In addition, cells were also pretreated with MG132 (10 mM) for 24 h, followed by treatment with MS-275 (1 mM) for another 24 h. Cells were harvested and the expressions of DR4 and DR5 were measured by the Western blot analysis. b-Actin was used as a loading control. (f) Effects of HDAC inhibitors on the expression of NFkB subunits c-Rel, p65, and p50. MDA-MB-231 and MDA-MB-468 cells were treated with MS-275 (1 mM) or TSA (50 nM) for 24 h, and expression of c-Rel, p65, and p50 was determined by the Western blot analysis. b-Actin was used as a loading control
In addition to p53, other transcription factors such as NFkB and SP1 have been shown to regulate the expression of DR4 and/or DR5 (Ravi et al., 2001; Chen et al., 2003; Kim et al., 2004) . The oncogenic role of NFkB was observed in leukemia and lymphoma (Gil et al., 2001) , breast cancer (Sovak et al., 1997; Chen et al., 2003) , and pancreatic cancer (Wang et al., 1999) . In the present study, mIkBa or MG132 inhibited HDAC inhibitor-induced DR4 and DR5 expression in cells harboring mutated p53, suggesting the regulation of DRs by NFkB when p53 is absent or mutated. Our data suggest that HDAC inhibitors regulate gene expression without affecting the expression of NFkB subunits (cRel, p65, and p50). We have recently shown that overexpression of the RelA subunit of NFkB inhibits caspase-8, DR4, and DR5 expressions and enhances expressions of cIAP1 and cIAP2 after TRAIL treatment . By comparison, overexpression of cRel enhances DR4, DR5, and Bcl-Xs and inhibits cIAP1, cIAP2, and survivin after TRAIL treatment. Thus, the bifunctional roles of NFkB, as an inhibitor or activator of apoptosis, depend on the relative concentrations of RelA and c-Rel subunits in the nucleus.
The inhibitor of apoptosis (IAP) proteins serve as key regulators of caspase activity . The IAPs identified in humans include cIAP-1, cIAP-2, NIAP, Livin/ML-IAP, survivin, and XIAP, all of which possess one or more cysteine/histidine-rich zinc-binding (baculovirus IAP repeat (BIR)) domains (Reed, 2000; Kasof and Gomes, 2001) . IAPs protect cells against apoptosis by acting as caspase inhibitors . The BIR1 and BIR2 domains of cIAP1 and cIAP2 (Roy et al., 1997) , NIAP (Maier et al., 2002) , and XIAP inhibit downstream caspase-3 and -7. The cIAP-1, cIAP-2 proteins, and XIAP have also been shown to block activation of upstream caspase-9 (Deveraux et al., 1998 . Livin contains a single BIR domain, and binding studies demonstrated specific interactions with caspase-9, -3, and -7 (Kasof and Gomes, 2001) . IAP proteins are regulated by interactions with the mitochondrial protein Smac/DIABLO, which may be released into the cytosol upon apoptotic stimulation and through IAP sequestration results in elevated caspase activity (Du et al., 2000; Verhagen et al., 2000) . Some IAP proteins are also regulated by proteolysis via the ubiquitin-proteasome pathway (Yang et al., 2000) , and caspase-dependent cleavage of IAPs in cells undergoing apoptosis (Herrera et al., 2002) . Our studies showed that the pan-caspase inhibitor z-VAD-fmk blocked HDAC inhibitor-induced cIAP1 cleavage, which indicates that cIAP1 is a caspase substrate. The cleavage of cIAP1 and inhibition of XIAP and cIAP2 expressions by HDAC inhibitors may contribute to sensitization of TRAIL-resistant cells.
Altered regulation of apoptosis has been linked to the development of cancer (Johnstone, 2002) , and mitochondria have emerged as gatekeepers in many apoptotic signaling pathways Kandasamy et al., 2003) . Members of the Bcl-2 family of proteins that regulate apoptotic signaling through mitochondria are key regulators of apoptosis in mammalian development, and their deregulation is associated with disease, particularly cancer (Gross et al., 1999a) . There are three classes of Bcl-2 family members: apoptosis promoters (e.g. Bax and Bak); apoptosis inhibitors (e.g. Bcl-2, Bcl-X L , and adenoviral E1B 19K); and the BH3-only Bcl-2 family members (e.g. Bid, Puma, Noxa, Bad, and Nbk/ Bik), that contain the BH3 interaction domain and that act as apoptosis promoters and inhibitors (Gross et al., 1999a) . Signal transduction events modify the activity of BH3-only proteins that, in turn, interact with pro-or antiapoptotic family members to either antagonize or activate their function. Stimulation of apoptosis can therefore be achieved by activating a death activity or by antagonizing a survival activity.
HDAC inhibitors induced proapoptotic molecules Bax and Bak. Bax and Bak function in a redundant capacity to facilitate the release of cytochrome c from the mitochondria Kandasamy et al., 2003) . We have recently shown that, unlike cytochrome c release, TRAIL-induced Smac/DIABLO release was blocked in Bax À/À , Bak
, or Bax À/À and Bak À/À double knockout mouse embryonic fibroblasts (DKO MEFs), suggesting the differential regulation of these mitochondrial proteins during apoptosis . Bax À/À and Bak À/À DKO MEFs are also resistant to death signaling by overexpression of BH3-only proteins, indicating that they are the required downstream components of these signaling pathways Wei et al., 2001) . Inactivation of both Bax and Bak was required for tumor growth and was selected for in vivo during tumorigenesis (Degenhardt et al., 2002) .
We have previously shown that the activation of TRAIL-DR pathway also engages the mitochondria (Suliman et al., 2001) . The activation of caspase-8 by TRAIL is necessary but may not be sufficient to induce apoptosis. Crosstalk between the death-receptor and mitochondrial pathways is mediated by caspase-8 cleavage of Bid (Li et al., 1998; Luo et al., 1998; Gross et al., 1999b; Suliman et al., 2001) . Truncated Bid (tBid) activates proapoptotic members Bax and Bak to release cytochrome c from the mitochondria . The proapoptotic Bcl-2 family member Bim has been shown to be dramatically upregulated by FOXO transcription factors (Dijkers et al., 2000 Stahl et al., 2002) . Withdrawal of cytokines from survival factor-dependent lymphocyte cell lines results in an upregulation of Bim expression, concomitant with the induction of apoptotic program. In the immune system, Bim has been critically implicated in modulating lymphocyte homeostasis. Bim À/À mice succumb to autoimmune kidney disease, accumulation of lymphoid and myeloid cells, and perturbed T-cell development (Bouillet et al., 2002) . In addition, lymphocytes were refractory to apoptotic stimuli and showed impaired negative selection. Our studies showed that the pancaspase inhibitor z-VAD-fmk completely inhibited TRAIL-induced apoptosis in the presence of HDAC inhibitors. Furthermore, in the presence of HDAC inhibitors, TRAIL enhanced caspase-3 and -9 activations, and PARP cleavage. Antiapoptotic proteins Bcl-2 and Bcl-X L blocked HDAC inhibitors and/or TRAILinduced apoptosis by blocking cytochrome c release. This suggests that HDAC inhibitors may act at the level of mitochondria to sensitize cells to TRAIL. The synergistic effects of HDAC inhibitors and TRAIL on apoptosis occur through activation of downstream caspase-3, which can be activated by both extrinsic and intrinsic pathways (Dijkers et al., 2000 Srivastava, 2000; Stahl et al., 2002) .
In summary, we have developed a novel strategy of combining HDAC inhibitors with TRAIL for the treatment of human breast cancer. Given that HDAC inhibitors upregulated a number of proapoptotic proteins and downregulated several antiapoptotic proteins, it is possible that sensitization of TRAIL-induced apoptosis may occur at various stages of apoptotic pathways. Firstly, induction of DRs would be expected to enhance the formation of active TRAIL-DISC. Secondly, upregulation of proapoptotic proteins in the TRAIL-induced apoptotic pathway, such as pro-caspase-8, Bax, and Bak, would be expected to amplify changes in MMP after TRAIL treatment. Thirdly, upregulation of the BH-3-only protein Bim, PUMA, and Noxa may act synergistically with tBid to enhance changes in MMP. Fourthly, downregulation of the antiapoptotic Bcl-2 and Bcl-X L may increase the available concentrations of tBid, Bim, PUMA, and Noxa, and enhance changes in MMP, leading to a greater release of apoptotic proteins from the mitochondria. Finally, downregulation of XIAP and cIAP1 may decrease their inhibition of active caspase-3, leading to enhanced processing of its substrates. Thus, our studies provide a novel strategy for the development of combined treatment regimens, involving HDAC inhibitors and TRAIL, to sensitize TRAIL-resistant breast cancer cells.
Materials and methods
Reagents
Antibodies against p50, Rel A (p65), c-Rel, p52, IkBa, Bcl-2, Bcl-X s , Bcl-X L , Bax, Bad, Bak, PUMA, Noxa, Bim, XIAP, survivin, cIAP1, and cIAP2 were from Santa Cruz Biotech. Inc. (Santa Cruz, CA, USA); antibodies against DR4 and DR5 were from IMGENEX Inc. (San Diego, CA, USA); antibody against actin was from Oncogene Research (Boston, MA, USA); antibodies against caspase-3, -9 and poly ADP ribose polymerase (PARP), and ELISA kits for DR4 and DR5 were from Biosource International, Inc. (Camarillo, CA, USA). Enhanced chemiluminescence (ECL) Western blot detection reagents were from Amersham Life Sciences Inc. (Arlington Heights, IL, USA). Annexin-V-FITC apoptosis detection kit was purchased from Oncogene Sciences (Boston, MA, USA). Antibodies against DR4, DR5, DcR1, and DcR2 (used in flow cytometry) were from R & D Systems Inc. (Minneapolis, MN, USA). Lipofectamine reagent was from Invitrogen Life Technologies (Carlsbad, CA, USA). TRAIL was synthesized as described earlier (Kim et al., 2001) . MS-275, CBHA, SAHA, and TSA were purchased from Calbiochem (San Diego, CA, USA) and Biomol (Plymouth Meeting, PA, USA). z-VAD-fmk and z-Ile-Glu-Thr-Asp-fluoromethylketone (z-IETD-fmk) were purchased from Enzyme Systems Products (Irvine, CA, USA). RPA kit was purchased from PharMingen (San Diego, CA, USA). All other chemicals used were of analytical grade from Fisher Scientific (Suwanee, GA, USA), Sigma (St Louis, MO, USA), and Calbiochem (San Diego, CA, USA).
Cells and culture conditions
MDA-MB-231, MCF-7, and MDA-MB-468 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin. Transfections of Bcl-2, Dloop-Bcl-2, Bcl-X L , and Dloop-Bcl-X L genes have been described (Srivastava et al., 1999c; Singh et al., 2003) . Normal breast epithelial cells were purchased from Cambrex Bio Science (Walkersville, MD, USA) and grown in MEGM medium.
Isobographic analysis
To analyse the effects of combined TRAIL and SAHA on MDA-MB-231 cells, we employed ED50 isobolographic analyses as described by Gessner (1995) and Tallarida (2002) . In brief, ED50 values for SAHA-induced apoptosis were determined in the presence of increasing amounts of TRAIL. These ED50 values were plotted against the corresponding TRAIL concentrations. Points representing an additive interaction fall on a diagonal straight line, the 'line of simple addition' (Gessner, 1995) . ED50 data points falling below this straight line and outside the 95% confidence intervals delineate a superadditive, that is, synergistic interaction.
RNase protection assay
Total RNAs were extracted using Trizolt reagent (Life Technologies Inc, Gaithersburg, MD, USA). The RPA was performed as per the manufacturer's instructions (PharMingen, San Diego, CA, USA). Briefly, a probe set including the DNA templates was used for T7 RNA polymerase-directed synthesis of 32 P-UTP-labeled antisense RNA probes. In all, 2 mg of RNA was incubated with a-32 P-UTP-labeled singlestranded RNA probes overnight at 561C, and treated with RNase for 45 min at 301C. The RNA-RNA complexes were resolved by electrophoresis in 6% denaturing polyacrylamide gels and analysed by autoradiography.
Western blot analysis
Cells were lysed in a buffer containing 10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 0.5 mM EDTA, 1 mM EGTA, 1% SDS, 1 mM sodium orthovanadate, and a mixture of protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mg/ml pepstatin A, 2 mg/ml aprotinin). Lysates were sonicated for 10 s, centrifuged for 20 min at 10 000 Â g and stored at À701C. Equal amounts of lysate proteins were run on 10% SDS-PAGE and electrophoretically transferred to nitrocellulose. Nitrocellulose blots were blocked with 6% nonfat dry milk in TBS buffer (20 mM Tris-HCl (pH 7.4) and 500 mM NaCl), and incubated with primary antibody in TBS containing 1% bovine serum albumin overnight at 41C. Immunoblots were washed three times (15, 5, and 5 min each) with TBST (TBS and 0.01% Tween 20). Immunoreactivity was detected by sequential incubation with horseradish peroxidase-conjugated secondary antibody and ECL reagents.
DR4 and DR5 ELISA
Cells were treated with TRAIL for 24 or 48 h. At the end of the incubation period, cells were harvested and washed twice with ice-cold PBS. Cells were lysed in extraction buffer for 30 min on ice with vortexing at 10 min intervals. The extracts were centrifuged at 13 000 r.p.m. for 10 min at 41C. Lysates were aliquoted, and assayed for DR4 and DR5 proteins by ELISA as per the manufacturer's directions (Biosource International, Inc.).
Assessment of cell-surface DRs
Cells were detached with 0.5 mM EDTA, and washed three times (spun at 500 g for 5 min) with an isotonic PBS wash buffer supplemented with 0.5% BSA. Cells (1 Â 10 5 ) were resuspended in 200 ml of PBS, stained with primary antibody (1 mg/ml), and incubated for 30 min at 41C. Unreacted antibody was removed by washing the cells twice with the same PBS buffer. Cells were stained with secondary antibody conjugated with phycoerythrin and incubated for 30 min at 41C. Unbound phycoerythrin-conjugated antibody was washed twice with PBS. Cells were resuspended in 200 ml of PBS. Cell-surface expressions of DR4, DR5, DcR1, and DcR2 receptors were determined by flow cytometry. Fluorescent intensity of the cells is directly proportional to the density of receptors.
Electrophoretic mobility shift assay
Nuclear extracts were prepared from cells. Double-stranded oligonucleotides containing the consensus-binding site for NFkB (GATCGAGGGGACTTTCCCTACG) (Promega) were 5 0 end-labeled using polynucleotide kinase and [g-32 P-dATP. Nuclear extracts (5.0 mg) were incubated with 1 ml of labeled oligonucleotide (20 000 c.p.m.) in 20 ml of incubation buffer (10 mM Tris-HCl, 40 mM NaCl, 1 mM EDTA, 1 mM bmercaptoethanol, 2% glycerol, and 2 mg of poly dI-dC) for 20 min at room temperature. The specificity of NFkB DNAbinding activity was confirmed by competition with excess cold wild-type or nonconsensus oligonucleotide. Supershift was performed by additional incubations with antibodies against p65, p50, c-Rel, or p52 for 45 min at 41C prior to incubation of the labeled oligonucleotide. DNA-protein complexes were resolved by electrophoresis in 6% nondenaturing polyacrylamide gels and analysed by autoradiography .
Reporter transfection and luciferase assay
The transcription activity of NFkB was determined by the transfection of luciferase reporter containing a specific consensus sequence of NFkB. In addition, cells were cotransfected with control plasmids (pCMV-LacZ) encoding the b-galactosidase enzyme. Luciferase activity was measured and normalized by b-galactosidase activity as per the manufacturer's directions (Promega).
Flow-cytometric analysis of sub-G 1 (hypodiploid) apoptotic cells Cells were harvested and fixed in 70% ethanol. Cells were then stained with 1 mg/ml propidium iodide (PI) in phosphatebuffered saline with 0.5% Nonidet P-40 and RNase A. PIstained cells were analysed using a Beckton Dickson FACStar flow cytometer. The percentage of sub-G 1 (hypodiploid) apoptotic cells was calculated using ModFit LT.
Assessment of apoptosis by annexin V staining
Cells were resuspended in 100 ml of staining solution (containing annexin V fluorescein and PI in a HEPES buffer; Annexin-V-FLUOS Staining Kit; Boehringer Mannheim). After incubation at room temperature for 20 min, cells were analysed by flow cytometry.
Statistical analysis
The mean and s.e.m. were calculated for each data point. Differences between groups were analysed by one-or two-way ANOVA. Differences in the rates of complete tumor inhibitions or survivors were validated by w 2 test. Survival curves were drawn according to Kaplan-Meier analysis. Significant differences among groups were calculated at Po0.05.
Abbreviations DR, death receptor; DcR, decoy receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; Apo-2L, Apo2 ligand; HDAC, histone deacetylase; TSA, trichostatin A; CBHA, m-carboxycinnamic acid bis-hydroxamide; SAHA, suberoylanilide hydroxamic acid; IAP, inhibitor of apoptosis protein; PARP, poly(ADP-ribose) polymerase; z-VAD-fmk, zVal-Ala-Asp-fluoromethylketone; z-IETD-fmk, z-Ile-Glu-ThrAsp-fluoromethylketone.
